Adenocarcinoma, Clear Cell
-
Subject Areas on Research
- Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer.
- Adverse health outcomes in women exposed in utero to diethylstilbestrol.
- An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
- Analgesic medication use and risk of epithelial ovarian cancer in African American women.
- Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.
- Cancer risk in women exposed to diethylstilbestrol in utero.
- Clear cell adenocarcinoma in a female urethral diverticulum.
- Common variants at 19p13 are associated with susceptibility to ovarian cancer.
- Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
- Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.
- Epigenetic determinants of ovarian clear cell carcinoma biology.
- Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma.
- High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
- Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes.
- Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
- Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk.
- Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.
- Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types.
- Mitochondrial Superoxide Dismutase Has a Protumorigenic Role in Ovarian Clear Cell Carcinoma.
- Molecular genetics and histopathologic features of adult distal nephron tumors.
- Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer.
- Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
- Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
- Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
- Predicting occult multifocality of renal cell carcinoma.
- Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.
- Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients.
- Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.
- Risk factors for ovarian cancers with and without microsatellite instability.
- Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.
- Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
- The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance.
- The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
-
Keywords of People
- Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
- Halabi, Susan, Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
- Moorman, Patricia Gripka, Professor in Community and Family Medicine, Duke Cancer Institute
- Yan, Hai, Henry S. Friedman Professor of Neuro-Oncology in the School of Medicine, Pathology